ICR welcomes recommendation of talazoparib for advanced breast cancer 19 Jan 2024 The Institute of Cancer Research, London, strongly welcomes the news that talazoparib (trade name Talzenna) has been recommended by NICE for the treatment of advanced breast cancer. Find out more Show/Hide
Study uncovers how cancers resist targeted treatment 10 Jan 2022 Scientists have revealed how cancer can resist PARP inhibitors, a precision medicine used to treat thousands of patients worldwide. Find out more Show/Hide
New BRCA-targeting drug could offer hope in treating advanced prostate cancer 22 Aug 2021 Talazoparib, a new precision drug, can keep cancer in check in some men with advanced prostate cancer who have run out of options, a phase II clinical trial shows. Find out more Show/Hide
The ICR responds to the FDA approval of talazoparib for women with BRCA-mutant advanced breast cancer 18 Oct 2018